Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy
-
- Yiting Qiao
- The First Affiliated Hospital; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases; Key Laboratory of Combined Multi‐Organ Transplantation, Ministry of Public Health, School of Medicine Zhejiang University Hangzhou P.R. China
-
- Jianqin Wan
- The First Affiliated Hospital; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases; Key Laboratory of Combined Multi‐Organ Transplantation, Ministry of Public Health, School of Medicine Zhejiang University Hangzhou P.R. China
-
- Liqian Zhou
- The First Affiliated Hospital; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases; Key Laboratory of Combined Multi‐Organ Transplantation, Ministry of Public Health, School of Medicine Zhejiang University Hangzhou P.R. China
-
- Wen Ma
- School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening Southern Medical University Guangzhou P.R. China
-
- Yuanyuan Yang
- School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening Southern Medical University Guangzhou P.R. China
-
- Weixuan Luo
- School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening Southern Medical University Guangzhou P.R. China
-
- Zhiqiang Yu
- School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening Southern Medical University Guangzhou P.R. China
-
- Hangxiang Wang
- The First Affiliated Hospital; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases; Key Laboratory of Combined Multi‐Organ Transplantation, Ministry of Public Health, School of Medicine Zhejiang University Hangzhou P.R. China
説明
<jats:p>Cancer remains one of the world's leading causes of death. However, most conventional chemotherapeutic drugs only show a narrow therapeutic window in patients because of their inability to discriminate cancer cells from healthy cells. Nanoparticle‐based therapeutics (termed nanotherapeutics) have emerged as potential solutions to mitigate many obstacles posed by these free drugs. Deep insights into knowledge of the tumor microenvironment and materials science make it possible to construct nanotherapeutics that are able to release cargoes in response to a variety of internal stimuli and external triggers. Therefore, such highly sophisticated nanosystems could help impede the premature release of toxic drugs in the blood circulation or healthy tissues, thus enhancing the safety profiles of encapsulated drugs. In this context, this review offers a comprehensive overview of several specific stimuli, including internal stimuli (e.g., pH, temperature, enzyme, redox, and H<jats:sub>2</jats:sub>O<jats:sub>2</jats:sub>) and external stimuli (e.g., magnetic, photo, and ultrasound). We envision that applications of these smart nanotherapeutics can benefit cancer patients and provide a good chance for clinical translation of many nanoparticle formulas.</jats:p><jats:p>This article is categorized under: <jats:list list-type="simple"> <jats:list-item><jats:p>Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease</jats:p></jats:list-item> <jats:list-item><jats:p>Diagnostic Tools > Diagnostic Nanodevices</jats:p></jats:list-item> <jats:list-item><jats:p>Diagnostic Tools > in vitro Nanoparticle‐Based Sensing</jats:p></jats:list-item> </jats:list> </jats:p>
収録刊行物
-
- WIREs Nanomedicine and Nanobiotechnology
-
WIREs Nanomedicine and Nanobiotechnology 11 (1), 2018-05-04
Wiley